<DOC>
	<DOCNO>NCT01848145</DOCNO>
	<brief_summary>This Phase II , single-arm study ofatumumab investigate safety accelerate infusion schedule ofatumumab patient receive least one prior therapy CLL . The primary endpoint evaluate number subject able complete infusion number 3 ( 2000 mg ) within 15 minute plan time .</brief_summary>
	<brief_title>Rapid Infusion Ofatumumab Patients With Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>The purpose study develop accelerated infusion regimen allow ofatumumab deliver safe manner minimize time require administering treatment . We hypothesize few infusion-related reaction use propose dose-dense approach first week accelerate rate infusion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . CD20+ Bcell chronic lymphocytic leukemia ( BCLL ) accord International Workshop CLL Working Group ( IWCLL WG ) Diagnostic Criteria . 2 . Have receive least one prior therapy CLL . â€¢If previously treat ofatumumab must achieve least partial response ( PR ) maintain PR &gt; = 6 month . 3 . Requires treatment accord IWCLLWorking Group guideline . 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) &lt; =1 . 5 . Laboratory parameter &lt; =7 day prior treatment initiation : 1 . Creatinine &lt; = 1.5 mg/dL upper limit normal ( ULN ) 2 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; = 3.0 x ULN 3 . Alkaline phosphatase ( ALP ) &lt; = 3.0 x ULN 4 . Total Bilirubin level &lt; 1.5 mg/dL x institutional ULN unless secondary Gilbert 's disease ( pattern consistent Gilbert 's ) 6 . Hepatitis B sAg negative HepB cAb negative . Note : Patients HepB sAg negative HepB cAb positive ( regardless HepB sAb status ) NOT allow . 7 . Women childbearing potential must negative serum pregnancy test perform &lt; =72 hour prior start treatment . Women childbearing potential men partner childbearing potential must use effective birth control measure treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 8 . Accessible treatment followup . 9 . Able understand nature study , give write informed consent prior study entry , comply study requirement . 10 . No prior antibody therapy CLL within previous 3 month . 1 . Previous treatment ofatumumab result Grade 3 4 infusion reaction . 2 . Treatment CLL within last 4 week . ( Patients receive steroid IVIG autoimmune complication CLL eligible ) . 3 . Current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis , stable chronic liver disease , per assessment treat physician ) . 4 . Active bacterial viral infection infection require intravenous antibiotic treatment time accrual . 5 . Central nervous system lymphoma/CLL . 6 . Transformation CLL aggressive nonHodgkin lymphoma ( NHL ) ( i.e. , Richter 's transformation ) . 7 . History malignancy &lt; = 2 year study entry could affect compliance protocol interpretation result . History curatively treat basal squamous cell carcinoma skin situ carcinoma cervix , low grade , earlystage , localized prostate cancer treat surgically curative intent , ductal carcinoma situ ( DCIS ) breast treat curative intent , generally eligible . 8 . Active hepatitis B C know HIV positive . 9 . Treatment known nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior visit 1 , whichever longer . 10 . History significant cerebrovascular disease past 6 month ongoing event active symptom sequela . 11 . Clinically significant cardiac disease include unstable angina , acute myocardial infarction ( within 6 month enrollment ) , congestive heart failure ( NYHA IIIIV ) , arrhythmia unless controlled therapy , exception extra systole minor conduction abnormality . 12 . Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease opinion investigator may represent risk patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Rapid Infusion</keyword>
</DOC>